Breast cancer takes approximately 670,000 lives annually. According to the World Health Organisation (WHO), breast cancer was the most prevalent cancer in women in 157 out of 185 countries in 2022. More than 2 million women are diagnosed with breast cancer each year, highlighting the importance of early detection and targeted treatment approaches. The US Food and Drug Administration (FDA) has authorized the use of Kisqali, also known as ribociclib, in combination with hormone therapy for early-stage breast cancer patients. This approval offers hope for patients concerned about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, slowing cancer progression by targeting proteins CDK4/6. Administered orally, Kisqali is typically prescribed for three weeks followed by a one-week break, to be continued for three years. Dosage of 400 mg is recommended daily, with or without food.Kisqali Edition: Adverse Effects

The typical adverse effects linked to Kisqali medication include reduced white blood cell count known as neutropenia. Neutropenia is characterized by decreased levels of neutrophils in the bloodstream, which are crucial for battling infections in the body. Kisqali may also lead to liver-related problems and interstitial lung disease/pneumonitis.

Breast Cancer: Warning Signs to Be Vigilant About